Health and economic impact of subcutaneous allergen
immunotherapy in patients with pollen-induced allergic
rhinoconjunctivitis: real-word evidence from the Czech Republic

J 2022

Health and economic impact of subcutaneous allergen immunotherapy in patients with pollen-induced allergic rhinoconjunctivitis: real-word evidence from the Czech Republic

TURKOVA, Barbora, Jan TUZIL, Barbora PILNACKOVA, Helena DOLEZALOVA, Daniela STROSOVA et. al.

Basic information

Original name

Health and economic impact of subcutaneous allergen immunotherapy in patients with pollen-induced allergic rhinoconjunctivitis: real-word evidence from the Czech Republic

Authors

TURKOVA, Barbora (203 Czech Republic), Jan TUZIL (203 Czech Republic, guarantor), Barbora PILNACKOVA (203 Czech Republic), Helena DOLEZALOVA (203 Czech Republic), Daniela STROSOVA (203 Czech Republic), Vit PETRU (203 Czech Republic), Ester SEBEROVA (203 Czech Republic) and Tomáš DOLEŽAL (203 Czech Republic, belonging to the institution)

Edition

IMMUNOTHERAPY, London, FUTURE MEDICINE LTD, 2022, 1750-743X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30102 Immunology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.800

RIV identification code

RIV/00216224:14110/22:00128329

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.2217/imt-2022-0143

UT WoS

000853009100001

Keywords in English

allergy; costs; economics; effectiveness; immunotherapy; pollen; rhinitis; rhinoconjunctivis; savings; subcutaneous

Abstract

V originále

Plain language summary Hay fever has become more frequent over the years, and allergen immunotherapy (AIT) remains the only treatment able to reduce both symptoms and the root cause of this condition. However, it is not clear whether the benefits outweigh the price of the therapy. In this study, we observed patients in the common practice and described the effectiveness, safety and costs of injected AIT for pollen-induced hay fever. Of 471 new AIT users, 317 completed three courses of treatment in 3 consecutive years. Symptoms improved in 96% of them; no serious adverse reactions were reported. The cost of symptom-relieving medication decreased by 49% and the cost of unscheduled physician visits decreased by 73%. Except for costs related to AIT administration, total healthcare costs decreased by 54% compared with the years before AIT. In clinical practice, injected AIT is an effective treatment which generates savings on other medication and unscheduled physician consultations. Tweetable abstract In Czech clinical practice, subcutaneous allergen immunotherapy is an effective treatment for allergic rhinoconjunctivitis, generating savings on symptomatic medication and unscheduled physician consultations. Background: The prevalence of allergic rhinoconjunctivitis (AR) has been increasing over the years, and allergen immunotherapy (AIT) remains the only disease-modifying treatment. However, cost-effectiveness data remain scarce. Methods: In this single-arm, noninterventional, prospective, multicenter study, we describe the effectiveness, safety and costs of subcutaneous AIT for pollen-induced allergic rhinoconjunctivitis. Results: Of 471 new AIT users, 317 completed three courses of treatment, and symptoms improved in 96%; no serious adverse reactions were reported. The cost of symptomatic medication decreased by 49% and the cost of unscheduled specialist visits decreased by 73%. Except for AIT administration, total healthcare costs decreased by 54% compared with the baseline pollen season without AIT. Conclusion: In clinical practice, subcutaneous AIT is an effective treatment generating savings on symptomatic medication and unscheduled consultations.

Citovat

TURKOVA, Barbora, Jan TUZIL, Barbora PILNACKOVA, Helena DOLEZALOVA, Daniela STROSOVA, Vit PETRU, Ester SEBEROVA and Tomáš DOLEŽAL. Health and economic impact of subcutaneous allergen immunotherapy in patients with pollen-induced allergic rhinoconjunctivitis: real-word evidence from the Czech Republic. IMMUNOTHERAPY. London: FUTURE MEDICINE LTD, 2022, vol. 14, No 14, p. 1109-1120. ISSN 1750-743X. Available from: https://dx.doi.org/10.2217/imt-2022-0143.

@article{2250079,
   author = {Turkova, Barbora and Tuzil, Jan and Pilnackova, Barbora and Dolezalova, Helena and Strosova, Daniela and Petru, Vit and Seberova, Ester and Doležal, Tomáš},
   article_location = {London},
   article_number = {14},
   doi = {http://dx.doi.org/10.2217/imt-2022-0143},
   keywords = {allergy; costs; economics; effectiveness; immunotherapy; pollen; rhinitis; rhinoconjunctivis; savings; subcutaneous},
   language = {eng},
   issn = {1750-743X},
   journal = {IMMUNOTHERAPY},
   title = {Health and economic impact of subcutaneous allergen immunotherapy in patients with pollen-induced allergic rhinoconjunctivitis: real-word evidence from the Czech Republic},
   url = {https://www.futuremedicine.com/doi/10.2217/imt-2022-0143},
   volume = {14},
   year = {2022}
}

TY  - JOUR
ID  - 2250079
AU  - Turkova, Barbora - Tuzil, Jan - Pilnackova, Barbora - Dolezalova, Helena - Strosova, Daniela - Petru, Vit - Seberova, Ester - Doležal, Tomáš
PY  - 2022
TI  - Health and economic impact of subcutaneous allergen immunotherapy in patients with pollen-induced allergic rhinoconjunctivitis: real-word evidence from the Czech Republic
JF  - IMMUNOTHERAPY
VL  - 14
IS  - 14
SP  - 1109-1120
EP  - 1109-1120
PB  - FUTURE MEDICINE LTD
SN  - 1750743X
KW  - allergy
KW  - costs
KW  - economics
KW  - effectiveness
KW  - immunotherapy
KW  - pollen
KW  - rhinitis
KW  - rhinoconjunctivis
KW  - savings
KW  - subcutaneous
UR  - https://www.futuremedicine.com/doi/10.2217/imt-2022-0143
N2  - Plain language summary Hay fever has become more frequent over the years, and allergen immunotherapy (AIT) remains the only treatment able to reduce both symptoms and the root cause of this condition. However, it is not clear whether the benefits outweigh the price of the therapy. In this study, we observed patients in the common practice and described the effectiveness, safety and costs of injected AIT for pollen-induced hay fever. Of 471 new AIT users, 317 completed three courses of treatment in 3 consecutive years. Symptoms improved in 96% of them; no serious adverse reactions were reported. The cost of symptom-relieving medication decreased by 49% and the cost of unscheduled physician visits decreased by 73%. Except for costs related to AIT administration, total healthcare costs decreased by 54% compared with the years before AIT. In clinical practice, injected AIT is an effective treatment which generates savings on other medication and unscheduled physician consultations. Tweetable abstract In Czech clinical practice, subcutaneous allergen immunotherapy is an effective treatment for allergic rhinoconjunctivitis, generating savings on symptomatic medication and unscheduled physician consultations. Background: The prevalence of allergic rhinoconjunctivitis (AR) has been increasing over the years, and allergen immunotherapy (AIT) remains the only disease-modifying treatment. However, cost-effectiveness data remain scarce. Methods: In this single-arm, noninterventional, prospective, multicenter study, we describe the effectiveness, safety and costs of subcutaneous AIT for pollen-induced allergic rhinoconjunctivitis. Results: Of 471 new AIT users, 317 completed three courses of treatment, and symptoms improved in 96%; no serious adverse reactions were reported. The cost of symptomatic medication decreased by 49% and the cost of unscheduled specialist visits decreased by 73%. Except for AIT administration, total healthcare costs decreased by 54% compared with the baseline pollen season without AIT. Conclusion: In clinical practice, subcutaneous AIT is an effective treatment generating savings on symptomatic medication and unscheduled consultations.
ER  -

TURKOVA, Barbora, Jan TUZIL, Barbora PILNACKOVA, Helena DOLEZALOVA, Daniela STROSOVA, Vit PETRU, Ester SEBEROVA and Tomáš DOLEŽAL. Health and economic impact of subcutaneous allergen immunotherapy in patients with pollen-induced allergic rhinoconjunctivitis: real-word evidence from the Czech Republic. \textit{IMMUNOTHERAPY}. London: FUTURE MEDICINE LTD, 2022, vol.~14, No~14, p.~1109-1120. ISSN~1750-743X. Available from: https://dx.doi.org/10.2217/imt-2022-0143.

Detailed Information on Publication Record